BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 25376296)

  • 61. Patients with CD133-negative colorectal liver metastasis have a poor prognosis after hepatectomy.
    Yamamoto S; Tanaka K; Takeda K; Akiyama H; Ichikawa Y; Nagashima Y; Endo I
    Ann Surg Oncol; 2014 Jun; 21(6):1853-61. PubMed ID: 24554065
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Expression and role of epithelial cell adhesion molecule in dysplastic nodule and hepatocellular carcinoma.
    Bae JS; Noh SJ; Jang KY; Park HS; Chung MJ; Park CK; Moon WS
    Int J Oncol; 2012 Dec; 41(6):2150-8. PubMed ID: 22993038
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Exploring stemness gene expression and vasculogenic mimicry capacity in well- and poorly-differentiated hepatocellular carcinoma cell lines.
    Lirdprapamongkol K; Chiablaem K; Sila-Asna M; Surarit R; Bunyaratvej A; Svasti J
    Biochem Biophys Res Commun; 2012 Jun; 422(3):429-35. PubMed ID: 22580004
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation.
    Zeng Z; Ren J; O'Neil M; Zhao J; Bridges B; Cox J; Abdulkarim B; Schmitt TM; Kumer SC; Weinman SA
    BMC Cancer; 2012 Dec; 12():584. PubMed ID: 23216644
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [The significance of immunohistochemistry in the investigation of liver neoplasms: differential diagnosis, prognostic markers].
    Pozharisskiĭ KM; Granov DA; Ten VP; Kubaĭbergenova AG; Leenman EE; Rasskazov AI
    Vopr Onkol; 2008; 54(4):417-33. PubMed ID: 18942395
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver.
    de Boer CJ; van Krieken JH; Janssen-van Rhijn CM; Litvinov SV
    J Pathol; 1999 Jun; 188(2):201-6. PubMed ID: 10398165
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma.
    Yamada S; Okumura N; Wei L; Fuchs BC; Fujii T; Sugimoto H; Nomoto S; Takeda S; Tanabe KK; Kodera Y
    Ann Surg Oncol; 2014 Nov; 21(12):3882-90. PubMed ID: 24833103
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Epithelial cell adhesion molecule-positive human hepatic neoplastic cells: development of combined hepatocellular-cholangiocarcinoma in mice.
    Ogasawara S; Akiba J; Nakayama M; Nakashima O; Torimura T; Yano H
    J Gastroenterol Hepatol; 2015 Feb; 30(2):413-20. PubMed ID: 25087473
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status.
    Shan YF; Huang YL; Xie YK; Tan YH; Chen BC; Zhou MT; Shi HQ; Yu ZP; Song QT; Zhang QY
    Med Oncol; 2011 Dec; 28(4):1012-6. PubMed ID: 20571936
    [TBL] [Abstract][Full Text] [Related]  

  • 70. High CD44s expression is associated with the EMT expression profile and intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy.
    Mima K; Hayashi H; Imai K; Kuroki H; Nakagawa S; Okabe H; Chikamoto A; Watanabe M; Beppu T; Baba H
    J Hepatobiliary Pancreat Sci; 2013 Apr; 20(4):429-34. PubMed ID: 23238743
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma.
    Schulze K; Gasch C; Staufer K; Nashan B; Lohse AW; Pantel K; Riethdorf S; Wege H
    Int J Cancer; 2013 Nov; 133(9):2165-71. PubMed ID: 23616258
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas.
    Nakatsukasa H; Ashida K; Higashi T; Ohguchi S; Tsuboi S; Hino N; Nouso K; Urabe Y; Kinugasa N; Yoshida K; Uematsu S; Ishizaki M; Kobayashi Y; Tsuji T
    Hepatology; 1996 Jul; 24(1):82-8. PubMed ID: 8707287
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Participation of liver cancer stem/progenitor cells in tumorigenesis of scirrhous hepatocellular carcinoma--human and cell culture study.
    Fujii T; Zen Y; Harada K; Niwa H; Masuda S; Kaizaki Y; Watanabe K; Kawashima A; Nakanuma Y
    Hum Pathol; 2008 Aug; 39(8):1185-96. PubMed ID: 18547618
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma.
    Di Tommaso L; Destro A; Fabbris V; Spagnuolo G; Laura Fracanzani A; Fargion S; Maggioni M; Patriarca C; Maria Macchi R; Quagliuolo M; Borzio M; Iavarone M; Sangiovanni A; Colombo M; Roncalli M
    Hepatology; 2011 May; 53(5):1549-57. PubMed ID: 21520170
    [TBL] [Abstract][Full Text] [Related]  

  • 75. An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression.
    Zhang P; Shi B; Gao H; Jiang H; Kong J; Yan J; Pan X; Li K; Zhang P; Yao M; Yang S; Gu J; Wang H; Li Z
    Cancer Immunol Immunother; 2014 Feb; 63(2):121-32. PubMed ID: 24177984
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, beta-catenin mutation, and favorable prognosis.
    Yuan RH; Jeng YM; Chen HL; Hsieh FJ; Yang CY; Lee PH; Hsu HC
    Clin Cancer Res; 2005 Apr; 11(7):2568-75. PubMed ID: 15814635
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.
    Qin LX; Tang ZY
    J Cancer Res Clin Oncol; 2004 Sep; 130(9):497-513. PubMed ID: 15205947
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cancer stem cells in hepatocellular carcinoma--an immunohistochemical study with histopathological association.
    Matthai SM; Ramakrishna B
    Indian J Med Res; 2015 Oct; 142(4):391-8. PubMed ID: 26609030
    [TBL] [Abstract][Full Text] [Related]  

  • 79. An immunohistochemical analysis of 13 cases with combined hepatocellular and cholangiocellular carcinoma.
    Haratake J; Hashimoto H
    Liver; 1995 Feb; 15(1):9-15. PubMed ID: 7539881
    [TBL] [Abstract][Full Text] [Related]  

  • 80. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.
    Cai MY; Tong ZT; Zheng F; Liao YJ; Wang Y; Rao HL; Chen YC; Wu QL; Liu YH; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
    Gut; 2011 Jul; 60(7):967-76. PubMed ID: 21330577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.